🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 458173101
- Market Cap
- Micro Cap · $54 Million
- IPO
- 3/12/2012 · $2.75/share
- Previous Symbol
- IPCI (changed 3/21/2019)
Business: Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company’s patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology, Intellipharmaceutics has a pipeline of product candidates in various stages of development, including eight ANDAs as having been filed with the FDA, in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes, pain.
Notes: March 19, 2019 -- Intellipharmaceutics International Inc. (Nasdaq and TSX: IPCI) ), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced that today the Company received formal notice that the Nasdaq Hearings Panel had determined to delist the Company's shares from The Nasdaq Stock Market LLC ("Nasdaq") based upon the Company's non-compliance with the $1.00 bid price requirement, as set forth in Nasdaq Listing Rule 5550(a)(2). The suspension of trading on Nasdaq will take effect with the open of business on Thursday, March 21, 2019.
Company Contact
- CEO
- Isa Odidi
- CFO
- Shameze Rampertab
- Headquarters
- 30 Worcester Road, Toronto, M9W 5X2
- Phone
- 416-798-3001
- Fax
- 416-798-3007
- Investor Relations
- 416-798-3001 · investors@intellipharmaceutics.com